An app to prevent teens from smoking and encourage them to quit if they’ve started is now just a few taps away and available free on the Apple iTunes Store.
A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson Cancer Center report this week in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS).
Adults can avoid cancer-causing agents when they barbecue by using the healthy grilling tips in the new infographic, “How to fill a healthy barbecue plate,” created by experts at The University of Texas MD Anderson Cancer Center.
MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
Many glioblastoma patients treated with bevacizumab (Avastin®) have significant deterioration in neurocognitive function, symptoms and quality of life.
With tumor suppressors frozen in adolescence, resistant cancer cells cheat death, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports in Nature.
MD Anderson is leading efforts to better understand the mechanisms behind the obesity-cancer connection, how obesity impacts cancer treatment outcomes and novel methods of prevention to curb cancer risk. Following a multidisciplinary approach, with various specialties and departments coming together to piece together this complex puzzle, researchers focus on obesity across the entire cancer continuum, from prevention to survivorship.
John Mendelsohn, M.D., director of The University of Texas MD Anderson Cancer Center’s Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and former president of MD Anderson, has been elected as a fellow of the American Academy of Arts and Sciences.
For her research focusing on the refinement of predictive biomarkers and improving outcomes in the field of metastatic colorectal cancer, Maria Pia Morelli, M.D., Ph.D., has been awarded the 2013 Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow.
Guillermina “Gigi” Lozano, Ph.D., chair and professor in the Department of Genetics at The University of Texas MD Anderson Cancer Center, is the recipient of the 16th annual Women in Cancer Research Charlotte Friend Memorial Lectureship awarded by The American Association for Cancer Research (AACR), recognizing her contributions to the field of cancer research and the advancement of women in science.
Selected for its ability to target tumors precisely while minimizing damage to healthy surrounding tissue, proton therapy has rapidly gained a foothold as an option for radiation treatment in the past decade. The Proton Therapy Center at The University of Texas MD Anderson Cancer Center in Houston, Texas, continues to innovate the field by being the first and only center in North America to treat patients with the most advanced form of proton therapy, called intensity modulated proton therapy with multi-field optimization (IMPT).
Adults can learn how to increase their daily consumption of whole grains by using a new whole grain infographic created by experts at The University of Texas MD Anderson Cancer Center.
Pro Football Hall of Fame member and "Dancing with the Stars" champion Emmitt Smith will be the honoree of the sixth annual A Conversation With a Living Legend luncheon, Monday, April 29, benefiting The University of Texas MD Anderson Cancer Center. The luncheon will be held at the Hilton Americas hotel in downtown Houston.
Cancer vaccines that attempt to stimulate an immune system assault fail because the killer T cells aimed at tumors instead find the vaccination site a more inviting target, scientists at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Helen Piwnica-Worms, Ph.D., a leader and scientist whose success in cancer research spans the spectrum from basic science discovery through arduous preclinical follow up and delivery of potential new drugs to clinical trial, will lead science research at The University of Texas MD Anderson Cancer Center starting June 1.
Physician-scientist David Piwnica-Worms, M.D., Ph.D. whose creative and pioneering approach to visually capturing molecular processes in action has made him a leader in the field, will assume two important leadership posts at The University of Texas MD Anderson Cancer Center.
Adults can learn how to choose snacks that offer more cancer-fighting nutrients by using the new healthy snack combo infographic, created by experts at The University of Texas MD Anderson Cancer Center.
Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.
Scientists who built a synthetic gene circuit that allowed for the precise tuning of a gene's expression in yeast have now refined this new research tool to work in human cells, according to research published online in Nature Communications.
Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
Blood vessels that supply oxygen and nutrients to tumors can also deliver something else - a signal that strengthens nearby cancer cells, making them more resistant to chemotherapy, more likely to spread to other organs and more lethal, scientists at The University of Texas MD Anderson Cancer Center report online in Cancer Cell.